Medicare Plans Should Halt Off-Label Avastin Step Therapy Amid Supply Disruption, CMS Told

 
• By Cathy Kelly

The leading supplier of repackaged off-label Avastin for ophthalmic uses is discontinuing the product. Is this the beginning of the end for a relatively cheap wet AMD treatment?

Prescribers have long opposed step therapy in the anti-VEGF category. (Shutterstock)

More from Medicare

More from Geography